Stockreport

Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)

DOVA PHARMACEUTICALS  (DOVA) 
Last dova pharmaceuticals earnings: 11/12 06:05 am Check Earnings Report
US:NASDAQ Investor Relations: investors.dova.com/investor-relations
PDF Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conferen [Read more]